ProPharma Welcomes Marshall Florence as Vice President of Labeling & Strategy
Advancing Strategic Labeling for the Future
On July 8, 2025, ProPharma, a premier provider of regulatory, clinical, and compliance services within the life sciences sector, announced the appointment of Marshall Florence, PharmD, as the new Vice President of Labeling & Strategy. His extensive background includes key roles at the U.S. Food and Drug Administration (FDA) where he focused on drug labeling, providing a significant boost to ProPharma's capabilities in this vital area.
Florence arrives at ProPharma with over 15 years of specialized expertise in regulatory promotional review and labeling services. His prior experience at the FDA included being a Supervisory Pharmacist in the Division of Labeling Review. Here, he played a crucial role in overseeing the labeling of drug products, guiding them through both primary and secondary assessments, and contributing to initiatives like the Best Pharmaceuticals for Children Act (BPCA) Working Group.
Enhancing Client Portfolios and Strategies
As ProPharma continues to push the boundaries of regulatory science, Florence's leadership in compliance and regulatory advisory services will be pivotal for clients in the pharmaceutical, biotechnology, medical device, and diagnostic industries. His appointment signifies ProPharma’s commitment to delivering comprehensive solutions that incorporate not just regulatory compliance but also strategic development to meet business goals.
Matthew Weinberg, ProPharma's President of Regulatory Sciences, expressed enthusiasm about Florence’s role, stating, "His leadership experience at the FDA and deep expertise in strategic label development significantly elevate our capabilities in advertising, promotional review, and drug development." Florence's unique insights into the regulatory landscape—especially concerning new molecular entities (NMEs), generics, and patents—will add substantial value to the services offered by ProPharma.
The company is eager to leverage Florence's extensive knowledge to guide clients throughout the development lifecycle, optimizing their strategies not just for compliance, but for commercial success. This enhancement aligns with ProPharma’s mission: to empower organizations in the life sciences sector to innovate confidently and efficiently.
Upcoming Webinars and Insights
In addition to his theoretical knowledge, Florence will share practical guidance through a webinar scheduled for July 22, 2025. This session will explore critical elements in crafting high-quality Abbreviated New Drug Application (ANDA) submissions and underline common pitfalls that lead to Complete Response Letters (CRLs). Those interested in attending are encouraged to register through ProPharma's official website.
A Pioneering Force in Regulatory Science
ProPharma, underpinned by over 20 years of experience, focuses on enhancing patient health by mitigating risks associated with introducing new therapies. Their expertise spans various domains including regulatory sciences, clinical research, and compliance. The addition of Florence promises a transformative impact not just on internal strategies, but across their client engagements as well.
Florence’s appointment also reflects ProPharma's strategic partnership with Odyssey Investment Partners, a private equity firm renowned for transforming middle-market businesses into high-performing enterprises. Together, they stand poised to deliver innovative solutions that not only comply with regulations but also propel growth and efficiency.
For more details about ProPharma's offerings and insights from Marshall Florence, visit
ProPharma Group.